Key Market Indicator:
Stock market news: In short news style a la Twitter/X. Everything that is relevant - at a glance. The entry page for the informed investor. Compact, worth knowing and always up to date. Directly from the IR departments of the companies.
DE0005659700
Mon, 11.10.2021
Eckert & Ziegler Strahlen- und Medizintechnik AG
Berlin, 11 October 2021 - Eckert & Ziegler Strahlen- und Medizintechnik AG (ISIN DE0005659700, TecDAX) has received from the Berlin City Government a 66-year long-term lease for an industrial property with 53,000 square feet (5,000 square meters) of factory floor located at the north eastern city limit of Berlin. The group plans to use the faci [ … ]
Mon, 27.09.2021
Eckert & Ziegler Strahlen- und Medizintechnik AG
Berlin, 27 September 2021. The Centre Hospitalier Universitaire de Nantes (CHU), the French university hospital serving the greater Nantes/Saint-Nazaire metropolitan area, has started to dose first patients with PENTIXAFOR, an innovative imaging compound for the initial staging of cancer patients with symptomatic multiple myelomas. The Ga-68 based [ … ]
Thu, 26.08.2021
Eckert & Ziegler Strahlen- und Medizintechnik AG
Berlin, 26 August 2021. Eckert & Ziegler (ISIN DE0005659700, TecDAX), has started the delivery of Technetium-99 generators in Brazil. The subsidiary Eckert & Ziegler Brasil Comercial Ltda. had recently received a license from the Brazilian health authority ANVISA as the first and only private company to import and distribute technetium gene [ … ]
Thu, 12.08.2021
Eckert & Ziegler Strahlen- und Medizintechnik AG
Berlin, 12 August 2021. Eckert & Ziegler Strahlen- und Medizintechnik AG (ISIN DE0005659700, TecDAX), achieved a new record result in the first half of 2021 with a net profit of € 22.3 million or € 1.08 per share. Revenues of the Group amounted to € 89.5 million and were thus 7% above the previous year's level.
Although a large part of this gro [ … ]
Mon, 09.08.2021
Eckert & Ziegler Strahlen- und Medizintechnik AG
Berlin, August 9, 2021. Eckert & Ziegler Radiopharma GmbH in Braunschweig, a subsidiary of Eckert & Ziegler Strahlen- und Medizintechnik AG (ISIN DE0005659700, TecDAX), has now received manufacturing authorization from the Lower Saxony authorities for several thorium and lutetium compounds in accordance with the German Medicines Act. This a [ … ]
Mon, 02.08.2021
Eckert & Ziegler Strahlen- und Medizintechnik AG
Berlin, 2 August 2021. Eckert & Ziegler (ISIN DE0005659700, TecDAX) acquired Ambientis Radioproteção, based in Sao Paulo, Brazil, effective July 31st, 2021 via its subsidiary Eckert & Ziegler Brasil Isotope Solutions Ltda (EZBIS). The business with annual sales in the low single-digit million range and 24 employees and specialists have been [ … ]
Tue, 27.07.2021
Eckert & Ziegler Strahlen- und Medizintechnik AG
Berlin, 27 July 2021. Based on initial, unaudited assessments, earnings of Berlin-based isotope specialists Eckert & Ziegler Strahlen- und Medizintechnik AG (ISIN DE0005659700) for the half year ending 30 June 2021 are higher than expected. The consolidated result in the first half of the year came up to approximately 22 mm EUR (previous year: [ … ]
Tue, 08.06.2021
Eckert & Ziegler Strahlen- und Medizintechnik AG
Berlin, 8 June 2021 - Myelo Therapeutics GmbH, an affiliate of Eckert & Ziegler (ISIN DE0005659700, TecDAX) focused on developing medical countermeasures (MCM) and therapies for cancer supportive care, announced that the U.S. National Institute of Allergy and Infectious Diseases (NIAID), part of the National Institutes of Health, extended their [ … ]
Thu, 03.06.2021
Eckert & Ziegler Strahlen- und Medizintechnik AG
Berlin, 3 June 2021. Eckert & Ziegler (ISIN DE0005659700, TecDAX) and Telix Pharmaceuticals (Telix) will cooperate closely in the commercialization of GalliaPharm(R) (68Ge/68Ga Generator) and investigational product Illuccix(R) (Kit for the preparation of Ga-68 PSMA-11 injection) in the United States. An agreement to this effect has now been si [ … ]
Tue, 18.05.2021
Eckert & Ziegler Strahlen- und Medizintechnik AG
Berlin, 18.05.2021. Eckert & Ziegler (ISIN DE0005659700, TecDAX) has signed an agreement with Telix Pharmaceuticals (Telix), an Australian-headquartered company, for the exclusive distribution of Illuccix(R) (Kit for the preparation of Ga-68 PSMA-11 injection) in Germany. Illuccix(R) is a preparation for imaging prostate cancer with positron em [ … ]